Panagiotis Karagiannis, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytarabine | 3 | 2022 | 697 | 0.950 |
Why?
|
Antibodies, Neoplasm | 3 | 2022 | 283 | 0.890 |
Why?
|
Cladribine | 1 | 2022 | 34 | 0.820 |
Why?
|
Mitoxantrone | 1 | 2020 | 148 | 0.720 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2020 | 259 | 0.610 |
Why?
|
Melanoma | 13 | 2023 | 5740 | 0.560 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2022 | 3623 | 0.560 |
Why?
|
Immunoglobulin E | 7 | 2023 | 1510 | 0.540 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 2013 | 306 | 0.380 |
Why?
|
Immunoglobulin G | 6 | 2021 | 4572 | 0.370 |
Why?
|
Sulfonamides | 1 | 2020 | 1988 | 0.360 |
Why?
|
B-Lymphocytes | 6 | 2023 | 4781 | 0.350 |
Why?
|
Myosin Type II | 2 | 2020 | 70 | 0.330 |
Why?
|
Antigens, Neoplasm | 4 | 2022 | 2003 | 0.290 |
Why?
|
Receptor, erbB-2 | 2 | 2018 | 2586 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11843 | 0.210 |
Why?
|
Tumor Escape | 3 | 2016 | 374 | 0.210 |
Why?
|
Daunorubicin | 1 | 2022 | 157 | 0.200 |
Why?
|
Immunization, Passive | 2 | 2014 | 621 | 0.180 |
Why?
|
Cell Movement | 3 | 2019 | 5223 | 0.170 |
Why?
|
Antineoplastic Agents | 3 | 2014 | 13708 | 0.170 |
Why?
|
Proteoglycans | 1 | 2023 | 807 | 0.170 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2021 | 171 | 0.170 |
Why?
|
Neoplasms | 5 | 2023 | 22386 | 0.170 |
Why?
|
Skin Neoplasms | 3 | 2016 | 5891 | 0.170 |
Why?
|
Cholangitis, Sclerosing | 1 | 2021 | 179 | 0.170 |
Why?
|
Immunotherapy | 4 | 2022 | 4728 | 0.150 |
Why?
|
Antibody Formation | 1 | 2022 | 1393 | 0.140 |
Why?
|
Actomyosin | 2 | 2015 | 115 | 0.140 |
Why?
|
rho-Associated Kinases | 2 | 2020 | 286 | 0.140 |
Why?
|
Interleukin-10 | 2 | 2013 | 1185 | 0.140 |
Why?
|
Folate Receptor 1 | 1 | 2017 | 41 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 647 | 0.140 |
Why?
|
Receptor, Adenosine A3 | 1 | 2015 | 4 | 0.120 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2017 | 355 | 0.120 |
Why?
|
Nicotinic Acids | 1 | 2015 | 33 | 0.120 |
Why?
|
Cytoskeleton | 1 | 2020 | 1179 | 0.120 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9263 | 0.120 |
Why?
|
Immunoglobulin Class Switching | 1 | 2016 | 289 | 0.120 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2014 | 102 | 0.110 |
Why?
|
Trinucleotide Repeat Expansion | 1 | 2015 | 254 | 0.110 |
Why?
|
Flow Cytometry | 2 | 2018 | 5904 | 0.110 |
Why?
|
Immunologic Surveillance | 1 | 2014 | 93 | 0.110 |
Why?
|
Janus Kinases | 1 | 2014 | 253 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2014 | 239 | 0.110 |
Why?
|
Neoplasms, Experimental | 2 | 2015 | 1232 | 0.100 |
Why?
|
Langerhans Cells | 1 | 2012 | 169 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1557 | 0.090 |
Why?
|
Receptors, IgE | 2 | 2014 | 375 | 0.090 |
Why?
|
Tumor Microenvironment | 5 | 2023 | 3939 | 0.090 |
Why?
|
Epidermis | 1 | 2014 | 539 | 0.090 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2014 | 635 | 0.090 |
Why?
|
Lymphocyte Activation | 1 | 2022 | 5495 | 0.090 |
Why?
|
Dermatitis | 1 | 2012 | 203 | 0.090 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 873 | 0.090 |
Why?
|
Mice, Inbred NOD | 3 | 2021 | 1839 | 0.080 |
Why?
|
Cell Polarity | 1 | 2013 | 639 | 0.080 |
Why?
|
Receptors, IgG | 1 | 2013 | 564 | 0.080 |
Why?
|
Models, Immunological | 1 | 2012 | 518 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2021 | 2399 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2020 | 2072 | 0.080 |
Why?
|
Coculture Techniques | 1 | 2013 | 1343 | 0.080 |
Why?
|
Interleukin-4 | 1 | 2013 | 1158 | 0.080 |
Why?
|
Cloning, Molecular | 1 | 2014 | 4175 | 0.080 |
Why?
|
Humans | 31 | 2023 | 768451 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2562 | 0.080 |
Why?
|
Huntington Disease | 1 | 2015 | 1145 | 0.080 |
Why?
|
Mice, SCID | 3 | 2020 | 2633 | 0.070 |
Why?
|
Antigens, Surface | 1 | 2012 | 1615 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2015 | 2003 | 0.070 |
Why?
|
Th2 Cells | 1 | 2013 | 1079 | 0.070 |
Why?
|
Embryonic Stem Cells | 1 | 2014 | 1249 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.070 |
Why?
|
Myocytes, Cardiac | 1 | 2015 | 1683 | 0.070 |
Why?
|
Animals | 16 | 2023 | 169418 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3735 | 0.060 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 1625 | 0.060 |
Why?
|
Mice | 9 | 2023 | 82045 | 0.060 |
Why?
|
Cell Line, Tumor | 6 | 2020 | 17149 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4362 | 0.060 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 6135 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2930 | 0.060 |
Why?
|
Protein Engineering | 1 | 2008 | 549 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2015 | 2731 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2014 | 3417 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5342 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3619 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 3108 | 0.050 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2023 | 142 | 0.050 |
Why?
|
Phagocytosis | 1 | 2008 | 1531 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2020 | 5709 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6537 | 0.050 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2014 | 1890 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3520 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5797 | 0.050 |
Why?
|
Mice, Nude | 2 | 2020 | 3635 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2008 | 21156 | 0.050 |
Why?
|
Homeostasis | 1 | 2012 | 3351 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2014 | 19041 | 0.040 |
Why?
|
Leukemia, B-Cell | 1 | 2020 | 86 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2015 | 11674 | 0.040 |
Why?
|
Cytokines | 2 | 2014 | 7449 | 0.040 |
Why?
|
Keratinocytes | 2 | 2015 | 879 | 0.040 |
Why?
|
Mutation | 2 | 2015 | 30243 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2017 | 4906 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2015 | 757 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3042 | 0.040 |
Why?
|
Monocytes | 1 | 2008 | 2591 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 11206 | 0.040 |
Why?
|
Azacitidine | 1 | 2020 | 336 | 0.040 |
Why?
|
Autoantigens | 1 | 2023 | 894 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2023 | 613 | 0.040 |
Why?
|
Interleukin-1alpha | 1 | 2019 | 86 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 30179 | 0.040 |
Why?
|
Female | 9 | 2020 | 396943 | 0.040 |
Why?
|
Cell Survival | 1 | 2008 | 5801 | 0.040 |
Why?
|
Receptor Cross-Talk | 1 | 2019 | 118 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6657 | 0.040 |
Why?
|
Adult | 5 | 2021 | 223542 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9505 | 0.040 |
Why?
|
Antigens | 1 | 2023 | 1443 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2022 | 81834 | 0.030 |
Why?
|
Rare Diseases | 1 | 2021 | 630 | 0.030 |
Why?
|
Smad2 Protein | 1 | 2015 | 144 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2425 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2022 | 1797 | 0.030 |
Why?
|
Male | 9 | 2022 | 364781 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2021 | 825 | 0.030 |
Why?
|
Cell Shape | 1 | 2015 | 371 | 0.030 |
Why?
|
Keratin-14 | 1 | 2014 | 57 | 0.030 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2014 | 83 | 0.030 |
Why?
|
Antigens, Plant | 1 | 2014 | 105 | 0.030 |
Why?
|
Documentation | 1 | 2020 | 913 | 0.030 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2014 | 171 | 0.030 |
Why?
|
Methotrexate | 1 | 2020 | 1722 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 4586 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1337 | 0.030 |
Why?
|
Antibody Affinity | 1 | 2014 | 252 | 0.030 |
Why?
|
Cricetulus | 1 | 2015 | 815 | 0.030 |
Why?
|
Signal Transduction | 4 | 2019 | 23638 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1489 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2017 | 1891 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1600 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2012 | 89 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2019 | 59680 | 0.020 |
Why?
|
RNA, Viral | 1 | 2020 | 2865 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2019 | 3103 | 0.020 |
Why?
|
CHO Cells | 1 | 2015 | 1382 | 0.020 |
Why?
|
Melanocytes | 1 | 2015 | 512 | 0.020 |
Why?
|
Permeability | 1 | 2014 | 725 | 0.020 |
Why?
|
Plant Proteins | 1 | 2014 | 376 | 0.020 |
Why?
|
Protein Binding | 2 | 2015 | 9376 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2150 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2014 | 903 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2012 | 107 | 0.020 |
Why?
|
Cell Cycle | 1 | 2020 | 2942 | 0.020 |
Why?
|
Cricetinae | 1 | 2015 | 2423 | 0.020 |
Why?
|
Teratoma | 1 | 2014 | 405 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2014 | 949 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 22365 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2015 | 2298 | 0.020 |
Why?
|
Lectins, C-Type | 1 | 2014 | 589 | 0.020 |
Why?
|
NF-kappa B | 1 | 2019 | 2491 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1152 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2014 | 1355 | 0.020 |
Why?
|
DNA Primers | 1 | 2014 | 2826 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2461 | 0.020 |
Why?
|
Rats | 2 | 2017 | 23839 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6816 | 0.020 |
Why?
|
Calcium-Binding Proteins | 1 | 2014 | 1085 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2015 | 1751 | 0.020 |
Why?
|
Species Specificity | 1 | 2014 | 2422 | 0.020 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 1482 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15609 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2014 | 3594 | 0.020 |
Why?
|
Aged | 3 | 2020 | 171520 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2020 | 3145 | 0.020 |
Why?
|
Pluripotent Stem Cells | 1 | 2015 | 808 | 0.020 |
Why?
|
Receptors, Fc | 1 | 2011 | 539 | 0.020 |
Why?
|
Epitopes | 1 | 2014 | 2526 | 0.020 |
Why?
|
Phosphorylation | 1 | 2019 | 8332 | 0.020 |
Why?
|
Models, Animal | 1 | 2014 | 2126 | 0.020 |
Why?
|
Cholecalciferol | 1 | 2012 | 557 | 0.020 |
Why?
|
Middle Aged | 3 | 2020 | 223418 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2014 | 1669 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4138 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3637 | 0.020 |
Why?
|
Trans-Activators | 1 | 2015 | 2858 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10273 | 0.020 |
Why?
|
Immune System | 1 | 2011 | 801 | 0.020 |
Why?
|
Transcription Factors | 2 | 2015 | 12174 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3901 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 6091 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4931 | 0.010 |
Why?
|
Indoles | 1 | 2012 | 1834 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3816 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 8201 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6242 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2020 | 65409 | 0.010 |
Why?
|
Base Sequence | 1 | 2014 | 12428 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2834 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8559 | 0.010 |
Why?
|
Skin | 1 | 2016 | 4520 | 0.010 |
Why?
|
Escherichia coli | 1 | 2014 | 4220 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17647 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7605 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5808 | 0.010 |
Why?
|
Fibroblasts | 1 | 2011 | 4180 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9507 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 8635 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4421 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2012 | 3080 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6278 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2011 | 11138 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14480 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13655 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22293 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 40271 | 0.010 |
Why?
|
Cohort Studies | 1 | 2011 | 41797 | 0.000 |
Why?
|